A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial

Abstract

Gradual but definite progress has been made in the treatment of younger adults with acute myeloid leukaemia (AML) [ 1 , 2 , 3 ], except those 25–30% with high-risk disease. For them the best approach is a myeloablative allogeneic transplant; however, even the transplant option provides only a 30% chance of cure, and has been limited to younger patients who have a donor. The point at which a patient is recognised to be at high risk is usually after the first course of induction treatment has been given when the most useful prognostic data is to hand.